Xeris Biopharma Holdings, Inc. $XERS Shares Sold by Rosalind Advisors Inc.

Rosalind Advisors Inc. reduced its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 16.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,795,766 shares of the company’s stock after selling 359,828 shares during the quarter. Xeris Biopharma comprises 5.1% of Rosalind Advisors Inc.’s holdings, making the stock its 6th biggest position. Rosalind Advisors Inc. owned 1.08% of Xeris Biopharma worth $14,618,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Royal Bank of Canada grew its position in shares of Xeris Biopharma by 1,411.2% during the 1st quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock worth $1,170,000 after buying an additional 198,984 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Xeris Biopharma by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock valued at $461,000 after buying an additional 3,594 shares during the period. Millennium Management LLC boosted its stake in Xeris Biopharma by 19.0% in the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock valued at $12,726,000 after acquiring an additional 369,420 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after acquiring an additional 1,199,435 shares during the period. Finally, Caxton Associates LLP acquired a new stake in Xeris Biopharma during the 1st quarter worth $170,000. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Trading Down 4.4%

XERS opened at $5.48 on Friday. The firm’s fifty day moving average is $6.94 and its two-hundred day moving average is $7.53. The firm has a market cap of $944.92 million, a PE ratio of -547.45 and a beta of 0.61. Xeris Biopharma Holdings, Inc. has a twelve month low of $3.81 and a twelve month high of $10.08. The company has a debt-to-equity ratio of 16.10, a quick ratio of 1.57 and a current ratio of 2.19.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings results on Monday, March 2nd. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.03. Xeris Biopharma had a net margin of 0.19% and a negative return on equity of 5.33%. The company had revenue of $85.81 million during the quarter, compared to analyst estimates of $86.00 million. Equities research analysts anticipate that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

Analysts Set New Price Targets

XERS has been the topic of a number of analyst reports. Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Xeris Biopharma in a research note on Monday, March 2nd. Weiss Ratings upgraded Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a report on Wednesday, March 4th. Finally, Barclays assumed coverage on Xeris Biopharma in a report on Monday, December 8th. They set an “overweight” rating and a $9.00 target price on the stock. Four research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $10.80.

Insiders Place Their Bets

In other news, insider John Patrick Shannon, Jr. sold 24,907 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $7.08, for a total transaction of $176,341.56. Following the sale, the insider owned 2,705,346 shares of the company’s stock, valued at $19,153,849.68. This trade represents a 0.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director John Johnson sold 135,400 shares of Xeris Biopharma stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $7.22, for a total value of $977,588.00. Following the transaction, the director owned 698,083 shares in the company, valued at $5,040,159.26. This trade represents a 16.25% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 225,308 shares of company stock valued at $1,626,103 in the last three months. Insiders own 6.47% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.